Three lots of Promacta (eltrombopag; Novartis) for oral suspension 12.5mg are being recalled due to possible peanut flour contamination at a third-party manufacturer. Three lots of Promacta ...

New oral suspension formulation, designed for younger children with rare blood disorder, is now approved For about one in four children with ITP, the condition persists for more than 12 months after ...

Novartis announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral suspension lots are being recalled because of a risk of ...

Cross-contamination of products is an issue the FDA takes very seriously and will inevitably result in product recall. But rarely, if ever, has there been a recall of a drug because it was potentially ...

The FINANCIAL — Novartis announced on August 24 that the US Food and Drug Administration (FDA) has approved an expanded use for Promacta (eltrombopag) to include children 1 year of age and older with ...

The company is recalling the lots because of possible peanut flour contamination. Novartis announced on May 11, 2019 that it was recalling three lots of Promacta (eltrombopag) 12.5 mg for oral ...

Novartis today announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral suspension lots are being recalled because of a risk of ...

EAST HANOVER, N.J., Oct. 18, 2017 /PRNewswire/ -- Novartis today announced long-term study results supporting the positive safety and efficacy of Promacta (eltrombopag) in adults with ...

Novartis AG (NYSE: NVS) is one of the few companies with good news on a major market sell-off. Unfortunately, it is not big enough news to be moving the shares. The Swiss drug giant announced on ...

Novartis announced today that the US Food and Drug Administration (FDA) has approved an expanded use for Promacta ® (eltrombopag) to include children 1 year of age and older with chronic immune ...